Medeze Group PCL (BKK:MEDEZE) ROC % : 6.73% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Medeze Group PCL ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Medeze Group PCL's annualized return on capital (ROC %) for the quarter that ended in Mar. 2024 was 6.73%.

As of today (2025-04-04), Medeze Group PCL's WACC % is 10.44%. Medeze Group PCL's ROC % is 6.73% (calculated using TTM income statement data). Medeze Group PCL earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Medeze Group PCL ROC % Historical Data

The historical data trend for Medeze Group PCL's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeze Group PCL ROC % Chart

Medeze Group PCL Annual Data

Trend

Dec23

Dec24

ROC %

31.00

32.45

Medeze Group PCL Semi-Annual Data
	Mar23	Mar24
ROC %	-	6.73

Medeze Group PCL ROC % Calculation

Medeze Group PCL's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

	ROC % (A: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2023 )	+	Invested Capital (A: Dec. 2024 ))	/ count )
=	364.194 * ( 1 - 8.12% )	/	( (797.695	+	1264.551)	/ 2 )
=	334.6214472	/	1031.123
=	32.45 %

where

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1019.208	-	92.611	-	( 193.473	-	max(0, 137.795	-	266.697	+	193.473	))
=	797.695

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3429.039	-	63.372	-	( 2103.639	-	max(0, 124.659	-	2225.775	+	2103.639	))
=	1264.551

Medeze Group PCL's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	70.318 * ( 1 - 16.93% )	/	( (0	+	867.641)	/ 1 )
=	58.4131626	/	867.641
=	6.73 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1118.027	-	109.981	-	( 226.578	-	max(0, 161.048	-	301.453	+	226.578	))
=	867.641

Note: The Operating Income data used here is one times the annual (Mar. 2024) data.

Medeze Group PCL (BKK:MEDEZE) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Medeze Group PCL's WACC % is 10.44%. Medeze Group PCL's ROC % is 6.73% (calculated using TTM income statement data). Medeze Group PCL earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Medeze Group PCL ROC % Related Terms

Thank you for viewing the detailed overview of Medeze Group PCL's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medeze Group PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Medeze Group PCL (BKK:MEDEZE) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Phuttha Monthon Sai 4 Road, 28/9 Moo 8, Krathum Lom, Sam Phran, Nakhon Pathom, THA, 73220

Website

https://www.medezegroup.com

Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment.

Medeze Group PCL Headlines

No Headlines